Second Edition
AIDS Medicines and diagnostics services
July 2015
A quick reference guide for health authorities and health-care workers
Revised 2015
Methodological field approaches for scientists with a basic background in entomology to prepare and implement a yellow fever entomological assessment during outbreaks
WHO has been alerted to concerns expressed related to the wording on episiotomy in specific situations. We have temporarily removed the publication from the website while we are doing a review of the evidence with in-house and external experts. We will make the publication available on the website o...nce the review is completed and any needed revisions are made. Please check the website!!!
more
Eradication of yaws in India | Éradication du pian en Inde - 17 April 2015, 90th Year / 17 Avril 2015, 90e Année | No. 16, 2015, 90, 161–168 | http://www.who.int/wer
How safe is our hospital sanitation? An example from a public hospital
This document has been developed as a guide to allinstitutions producing health care waste in planning and implementation of interventions that will reduce mismanagement of hazardous waste in Zambia.The National Health-Care Waste Management Plan for 2015 to 2019 provides an overv...iew of the situation analysis, the proposed activities and the health care facility waste generating processes in Zambia and presents options for minimizing health-care waste generation through source reduction. The hazardous wastes generated by health care facilities are a challenge in Zambia as handling, storage, transportation and final disposal leaves much to be desired.
more
A training tutorial for healthcare professionals
This ECDC tutorial presents the fundamental concepts of personal protective equipment (PPE) and barrier nursing to support preparedness in hospitals across Europe. It provides practical information on the proper use of PPE at the point of care, inclu...ding technical requirements and procurement aspects
more
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Principles and Target Product Criteria. Roadmap January 12, 2015
Interim emergency guidelines
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more